Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America.
Viola L, Marciano S, Colombato L, Coelho H, Cheinquer H, Bugarin G, Tatsch F, Carvalho-Filho RJ, Roblero JP, Varon A, Holguin J, Torres-Ibarra MR, Pérez-Ríos AM. Viola L, et al. Among authors: tatsch f. Ann Hepatol. 2020 Mar-Apr;19(2):161-165. doi: 10.1016/j.aohep.2019.09.006. Epub 2019 Oct 24. Ann Hepatol. 2020. PMID: 31718995 Free article.
Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H Jr, Tatsch F. Pessôa MG, et al. Among authors: tatsch f. Ann Hepatol. 2012 Jan-Feb;11(1):52-61. Ann Hepatol. 2012. PMID: 22166561 Free article. Clinical Trial.
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
Aronsohn A, Ancuta I, Caruntu F, Coppola C, Delic D, Digiacomo A, Dusheiko GM, Lengyel G, Marcellin P, Orlandini A, Pruthi J, Silva GF, Tallarico L, Schmitz M, Tatsch F, Korner E, Cheinquer H. Aronsohn A, et al. Among authors: tatsch f. J Viral Hepat. 2014 May;21(5):377-80. doi: 10.1111/jvh.12179. Epub 2013 Oct 17. J Viral Hepat. 2014. PMID: 24131506 Clinical Trial.
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.
Shiffman ML, Cheinquer H, Berg CP, Berg T, de Figueiredo-Mendes C, Dore GJ, Ferraz ML, Mendes-Corrêa MC, Lima MP, Parise ER, Rios AM, Reuter T, Sanyal AJ, Shafran SD, Hohmann M, Tatsch F, Bakalos G, Zeuzem S. Shiffman ML, et al. Among authors: tatsch f. Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24. Hepatol Int. 2014. PMID: 26202757
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
Harrison SA, Abdurakhmanov D, Shiffman ML, Bakulin I, Mazur W, Rodriguez-Torres M, Silva GF, Cheinquer H, Messinger D, Connell EV, McKenna M, Tatsch F, Reddy KR; PROGRESS Investigators. Harrison SA, et al. Among authors: tatsch f. J Clin Gastroenterol. 2013 Mar;47(3):271-9. doi: 10.1097/MCG.0b013e31826102eb. J Clin Gastroenterol. 2013. PMID: 22951527
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, Lengyel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torres M, Shiffman ML, Schmitz M, Tatsch F, Rizzetto M. Marcellin P, et al. Among authors: tatsch f. Hepatology. 2012 Dec;56(6):2039-50. doi: 10.1002/hep.25892. Epub 2012 Aug 8. Hepatology. 2012. PMID: 22706730 Clinical Trial.
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Mercade GE, Kho D, Petoumenos K, Marks P, Tatsch F, Dos Santos AGP, Gane E; SMART-C Study Group. Dore GJ, et al. Among authors: tatsch f. J Hepatol. 2020 Mar;72(3):431-440. doi: 10.1016/j.jhep.2019.10.010. Epub 2019 Oct 23. J Hepatol. 2020. PMID: 31655134 Free article. Clinical Trial.
Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M; Brazilian Pegasys Cooperative Study Group. Parise E, et al. Among authors: tatsch f. Braz J Infect Dis. 2006 Feb;10(1):11-6. doi: 10.1590/s1413-86702006000100003. Epub 2006 Jun 2. Braz J Infect Dis. 2006. PMID: 16767309 Free article.
34 results